Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-17 of 17 for your search:
Drug:
recombinant interferon alfa-2b
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
Other
Protocol IDs:
MM-ADJ-5
, NCT00226408
2.
PegIntron vs IntronA in CMAJCC Stage II (EADO 2001/CMII Trial).
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
Other
Protocol IDs:
9267-01
, 2001-034, NCT00221702
3.
GEM05 for Patients With Multiple Myeloma Under 65 Years
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
65 and under
Sponsor:
Other
Protocol IDs:
2005-001110-41
, NCT00461747
4.
Phase III Randomized Study of Depot Octreotide Acetate and Interferon alfa-2b Versus Depot Octreotide Acetate and Bevacizumab in Patients With Unresectable Metastatic or Locally Advanced, High-Risk Neuroendocrine Carcinoid Tumor
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
NCI
Protocol IDs:
SWOG-S0518
, S0518, NCT00569127
5.
Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC)
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
A6181065
, NCT00267748
6.
Phase II Study of Neoadjuvant Oxaliplatin, Doxorubicin Hydrochloride, Fluorouracil, and Recombinant Interferon Alfa-2b in Patients With Unresectable, Nonmetastatic Hepatocellular Carcinoma
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
16 to 75
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
SINGAPORE-OC-GI-01-06
, OC-GI-01-06, SINGAPORE-IRB-06-16-HEP, SINGAPORE-CTC0600327, SPRI-SINGAPORE-OC-GI-01-06, NCT00471484
7.
Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Mydelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Over 1
Sponsor:
Other
Protocol IDs:
2219
, NCT00548847
8.
Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
05-125
, NCT00610857
9.
Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
TORAVA
, ET2007-035, NCT00619268
10.
Phase II Study of KW2871 Combined With High Dose Interferon-alpha2b in Patients With Metastatic Cutaneous Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Over 18
Sponsor:
Other
Protocol IDs:
LUD2007-001
, UPCI07-023, UCH15689B, NCT00679289
11.
Phase I Study of Recombinant Vaccinia-CEA(6D)-TRICOM Vaccine and Recombinant Fowlpox-CEA(6D)-TRICOM Vaccine in Combination With Sargramostim (GM-CSF) and Interferon alfa-2b in Patients With Locally Advanced or Metastatic Carcinoembryonic Antigen (CEA)-Expressing Carcinoma
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
OSU-2005H0005
, 0312, 5633, NCI-5633, NCT00217373
12.
Phase I Study of Azacitidine and Interferon alfa-2b in Patients With Unresectable Stage III or IV Melanoma or Unresectable Stage IV Renal Cell Carcinoma
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
YALE-HIC-27409
, 7317, NCI-7317, NCT00217542
13.
Phase I Study of Sodium Stibogluconate and Interferon alfa-2b Followed by Cisplatin, Vinblastine, and Temozolomide in Patients With Advanced Melanoma or Other Malignancies
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Approved-not yet active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
CASE-3Y06
, Case 3Y06, NCT00498979
14.
Phase I Pilot Study of Adjuvant Interferon alfa-2b in Patients Who Have Undergone Surgical Resection for High-Risk or Metastatic Melanoma
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
12 and over
Sponsor:
NCI
Protocol IDs:
OSU-07033
, OSU 07033, OSU-2007C0057, NCT00634127
15.
Effect of Proactive Management of Side Effects on Treatment Compliance in Malignant Melanoma Patients on High-Dose Intron A Therapy (Study P04600)
Phase:
No phase specified
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
P04600
, NCT00723710
16.
Study of the Molecular Characteristics of Sensitive and Resistant Disease in Patients With Human T-cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia/Lymphoma Treated With Zidovudine, Recombinant Interferon alfa-2b, and PEG-Interferon alfa-2b
Phase:
No phase specified
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
SCCC-2007055
, SCCC 2007055, EPROST 20070805, NCT00854581
17.
Pilot Study of IFN a2b for Melanoma Patients
Phase:
No phase specified
Type:
Treatment
Status:
Approved-not yet active
Age:
18 and over
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
08-067
, NCT00871533
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
